25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Bionomics Ltd ADR
Buy, Hold or Sell?

Let's analyze Bionomics together

I guess you are interested in Bionomics Ltd ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bionomics Ltd ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Bionomics Ltd ADR

I send you an email if I find something interesting about Bionomics Ltd ADR.

1. Quick Overview

1.1. Quick analysis of Bionomics (30 sec.)










1.2. What can you expect buying and holding a share of Bionomics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
$1.13
Expected worth in 1 year
$-2.38
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-3.51
Return On Investment
-1,254.1%

For what price can you sell your share?

Current Price per Share
$0.28
Expected price per share
$0 - $0.575
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Bionomics (5 min.)




Live pricePrice per Share (EOD)
$0.28
Intrinsic Value Per Share
$-11.07 - $-3.29
Total Value Per Share
$-9.95 - $-2.16

2.2. Growth of Bionomics (5 min.)




Is Bionomics growing?

Current yearPrevious yearGrowGrow %
How rich?$14.9m$26.5m-$11.6m-78.0%

How much money is Bionomics making?

Current yearPrevious yearGrowGrow %
Making money-$14.3m-$10.1m-$4.1m-29.2%
Net Profit Margin-4,902.5%-359.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Bionomics (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#596 / 961

Most Revenue
#605 / 961

Most Profit
#625 / 961

Most Efficient
#845 / 961
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Bionomics?

Welcome investor! Bionomics's management wants to use your money to grow the business. In return you get a share of Bionomics.

First you should know what it really means to hold a share of Bionomics. And how you can make/lose money.

Speculation

The Price per Share of Bionomics is $0.2799. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bionomics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bionomics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.13. Based on the TTM, the Book Value Change Per Share is $-0.88 per quarter. Based on the YOY, the Book Value Change Per Share is $0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bionomics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.62-580.0%-1.62-580.0%-1.11-396.3%-0.81-290.6%-0.69-248.0%
Usd Book Value Change Per Share-0.88-313.5%-0.88-313.5%0.1865.6%0.1034.7%-0.10-35.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.025.7%0.012.8%
Usd Total Gains Per Share-0.88-313.5%-0.88-313.5%0.1865.6%0.1140.4%-0.09-32.4%
Usd Price Per Share2.20-2.20-6.99-1.84-0.92-
Price to Earnings Ratio-1.36--1.36--6.30--1.53--0.77-
Price-to-Total Gains Ratio-2.51--2.51-38.06-17.78-17.78-
Price to Book Ratio1.95-1.95-3.49-1.09-0.54-
Price-to-Total Gains Ratio-2.51--2.51-38.06-17.78-17.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2799
Number of shares3572
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.880.10
Usd Total Gains Per Share-0.880.11
Gains per Quarter (3572 shares)-3,134.73403.88
Gains per Year (3572 shares)-12,538.931,615.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-12539-1254922813881606
20-25078-2508845527763222
30-37617-3762768341634838
40-50156-5016691155516454
50-62695-62705113969398070
60-75234-75244136683279686
70-87773-877831594971411302
80-100311-10032218221110212918
90-112850-11286120501249014534
100-125389-12540022771387816150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%1.024.00.04.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%4.06.00.040.0%13.012.00.052.0%
Dividend per Share0.00.01.00.0%1.00.02.033.3%3.00.02.060.0%3.00.07.030.0%5.00.020.020.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%4.06.00.040.0%13.012.00.052.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Bionomics Ltd ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.878-0.8780%0.184-578%0.097-1004%-0.099-89%
Book Value Per Share--1.1251.1250%2.003-44%1.197-6%1.380-18%
Current Ratio--4.8674.8670%12.460-61%6.651-27%5.201-6%
Debt To Asset Ratio--0.2290.2290%0.129+78%0.361-37%0.442-48%
Debt To Equity Ratio--0.2970.2970%0.148+102%0.911-67%1.112-73%
Dividend Per Share----0%-0%0.016-100%0.008-100%
Eps---1.623-1.6230%-1.109-32%-0.813-50%-0.694-57%
Free Cash Flow Per Share---0.725-0.7250%-0.766+6%-0.527-27%-0.454-37%
Free Cash Flow To Equity Per Share---0.536-0.5360%0.184-391%-0.001-100%0.002-23305%
Gross Profit Margin--1.0071.0070%1.012-1%1.097-8%1.054-4%
Intrinsic Value_10Y_max---3.289--------
Intrinsic Value_10Y_min---11.072--------
Intrinsic Value_1Y_max---0.428--------
Intrinsic Value_1Y_min---0.755--------
Intrinsic Value_3Y_max---1.212--------
Intrinsic Value_3Y_min---2.588--------
Intrinsic Value_5Y_max---1.904--------
Intrinsic Value_5Y_min---4.759--------
Market Cap3707947.260-686%29144280.00029144280.0000%92599326.000-69%24348721.200+20%12174360.600+139%
Net Profit Margin---49.025-49.0250%-3.593-93%-13.069-73%-7.096-86%
Operating Margin---43.107-43.1070%-2.946-93%-12.495-71%-6.811-84%
Operating Ratio--51.04951.0490%4.622+1004%13.853+269%8.159+526%
Pb Ratio0.249-686%1.9551.9550%3.490-44%1.089+80%0.544+259%
Pe Ratio-0.172+87%-1.355-1.3550%-6.302+365%-1.531+13%-0.766-43%
Price Per Share0.280-686%2.2002.2000%6.990-69%1.838+20%0.919+139%
Price To Free Cash Flow Ratio-0.386+87%-3.036-3.0360%-9.129+201%-2.433-20%-1.216-60%
Price To Total Gains Ratio-0.319+87%-2.507-2.5070%38.062-107%17.778-114%17.778-114%
Quick Ratio--4.5754.5750%12.016-62%6.120-25%4.540+1%
Return On Assets---0.741-0.7410%-0.333-55%-0.319-57%-0.244-67%
Return On Equity---0.961-0.9610%-0.382-60%-0.523-46%-0.510-47%
Total Gains Per Share---0.878-0.8780%0.184-578%0.113-876%-0.091-90%
Usd Book Value--14909250.44014909250.4400%26534969.431-44%15855773.475-6%18282057.089-18%
Usd Book Value Change Per Share---0.878-0.8780%0.184-578%0.097-1004%-0.099-89%
Usd Book Value Per Share--1.1251.1250%2.003-44%1.197-6%1.380-18%
Usd Dividend Per Share----0%-0%0.016-100%0.008-100%
Usd Eps---1.623-1.6230%-1.109-32%-0.813-50%-0.694-57%
Usd Free Cash Flow---9599824.393-9599824.3930%-10143967.627+6%-6982181.113-27%-6018356.101-37%
Usd Free Cash Flow Per Share---0.725-0.7250%-0.766+6%-0.527-27%-0.454-37%
Usd Free Cash Flow To Equity Per Share---0.536-0.5360%0.184-391%-0.001-100%0.002-23305%
Usd Market Cap3707947.260-686%29144280.00029144280.0000%92599326.000-69%24348721.200+20%12174360.600+139%
Usd Price Per Share0.280-686%2.2002.2000%6.990-69%1.838+20%0.919+139%
Usd Profit---14324130.677-14324130.6770%-10145052.159-29%-7303391.785-49%-7018599.812-51%
Usd Revenue--292179.350292179.3500%2823224.684-90%1694285.021-83%5552625.280-95%
Usd Total Gains Per Share---0.878-0.8780%0.184-578%0.113-876%-0.091-90%
 EOD+3 -5MRQTTM+0 -0YOY+5 -295Y+6 -3010Y+8 -28

3.3 Fundamental Score

Let's check the fundamental score of Bionomics Ltd ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.172
Price to Book Ratio (EOD)Between0-10.249
Net Profit Margin (MRQ)Greater than0-49.025
Operating Margin (MRQ)Greater than0-43.107
Quick Ratio (MRQ)Greater than14.575
Current Ratio (MRQ)Greater than14.867
Debt to Asset Ratio (MRQ)Less than10.229
Debt to Equity Ratio (MRQ)Less than10.297
Return on Equity (MRQ)Greater than0.15-0.961
Return on Assets (MRQ)Greater than0.05-0.741
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Bionomics Ltd ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5022.879
Ma 20Greater thanMa 500.475
Ma 50Greater thanMa 1000.562
Ma 100Greater thanMa 2000.673
OpenGreater thanClose0.268
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Bionomics Ltd ADR

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Fundamental data was last updated by Penke on 2024-10-01 18:08:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Bionomics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bionomics to the Biotechnology industry mean.
  • A Net Profit Margin of -4,902.5% means that $-49.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bionomics Ltd ADR:

  • The MRQ is -4,902.5%. The company is making a huge loss. -2
  • The TTM is -4,902.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4,902.5%TTM-4,902.5%0.0%
TTM-4,902.5%YOY-359.3%-4,543.2%
TTM-4,902.5%5Y-1,306.9%-3,595.6%
5Y-1,306.9%10Y-709.6%-597.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,902.5%-118.4%-4,784.1%
TTM-4,902.5%-189.8%-4,712.7%
YOY-359.3%-206.6%-152.7%
5Y-1,306.9%-365.0%-941.9%
10Y-709.6%-471.8%-237.8%
4.3.1.2. Return on Assets

Shows how efficient Bionomics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bionomics to the Biotechnology industry mean.
  • -74.1% Return on Assets means that Bionomics generated $-0.74 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bionomics Ltd ADR:

  • The MRQ is -74.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -74.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-74.1%TTM-74.1%0.0%
TTM-74.1%YOY-33.3%-40.7%
TTM-74.1%5Y-31.9%-42.1%
5Y-31.9%10Y-24.4%-7.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-74.1%-10.9%-63.2%
TTM-74.1%-11.7%-62.4%
YOY-33.3%-11.2%-22.1%
5Y-31.9%-12.8%-19.1%
10Y-24.4%-14.4%-10.0%
4.3.1.3. Return on Equity

Shows how efficient Bionomics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bionomics to the Biotechnology industry mean.
  • -96.1% Return on Equity means Bionomics generated $-0.96 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bionomics Ltd ADR:

  • The MRQ is -96.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -96.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-96.1%TTM-96.1%0.0%
TTM-96.1%YOY-38.2%-57.8%
TTM-96.1%5Y-52.3%-43.8%
5Y-52.3%10Y-51.0%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-96.1%-14.2%-81.9%
TTM-96.1%-15.9%-80.2%
YOY-38.2%-13.6%-24.6%
5Y-52.3%-19.0%-33.3%
10Y-51.0%-19.5%-31.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Bionomics Ltd ADR.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Bionomics is operating .

  • Measures how much profit Bionomics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bionomics to the Biotechnology industry mean.
  • An Operating Margin of -4,310.7% means the company generated $-43.11  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bionomics Ltd ADR:

  • The MRQ is -4,310.7%. The company is operating very inefficient. -2
  • The TTM is -4,310.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4,310.7%TTM-4,310.7%0.0%
TTM-4,310.7%YOY-294.6%-4,016.1%
TTM-4,310.7%5Y-1,249.5%-3,061.2%
5Y-1,249.5%10Y-681.1%-568.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,310.7%-258.6%-4,052.1%
TTM-4,310.7%-292.1%-4,018.6%
YOY-294.6%-222.8%-71.8%
5Y-1,249.5%-386.0%-863.5%
10Y-681.1%-497.7%-183.4%
4.3.2.2. Operating Ratio

Measures how efficient Bionomics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 51.05 means that the operating costs are $51.05 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Bionomics Ltd ADR:

  • The MRQ is 51.049. The company is inefficient in keeping operating costs low. -1
  • The TTM is 51.049. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ51.049TTM51.0490.000
TTM51.049YOY4.622+46.427
TTM51.0495Y13.853+37.197
5Y13.85310Y8.159+5.694
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ51.0492.659+48.390
TTM51.0493.111+47.938
YOY4.6223.299+1.323
5Y13.8535.070+8.783
10Y8.1596.539+1.620
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Bionomics Ltd ADR.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Bionomics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.87 means the company has $4.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Bionomics Ltd ADR:

  • The MRQ is 4.867. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.867. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.867TTM4.8670.000
TTM4.867YOY12.460-7.593
TTM4.8675Y6.651-1.785
5Y6.65110Y5.201+1.451
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8673.788+1.079
TTM4.8674.004+0.863
YOY12.4604.740+7.720
5Y6.6515.970+0.681
10Y5.2016.324-1.123
4.4.3.2. Quick Ratio

Measures if Bionomics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bionomics to the Biotechnology industry mean.
  • A Quick Ratio of 4.58 means the company can pay off $4.58 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bionomics Ltd ADR:

  • The MRQ is 4.575. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.575. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.575TTM4.5750.000
TTM4.575YOY12.016-7.441
TTM4.5755Y6.120-1.545
5Y6.12010Y4.540+1.580
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5753.381+1.194
TTM4.5753.576+0.999
YOY12.0164.734+7.282
5Y6.1205.910+0.210
10Y4.5406.503-1.963
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Bionomics Ltd ADR.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Bionomics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bionomics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Bionomics assets are financed with 22.9% credit (debt) and the remaining percentage (100% - 22.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bionomics Ltd ADR:

  • The MRQ is 0.229. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.229. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.229TTM0.2290.000
TTM0.229YOY0.129+0.101
TTM0.2295Y0.361-0.132
5Y0.36110Y0.442-0.081
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2290.341-0.112
TTM0.2290.343-0.114
YOY0.1290.309-0.180
5Y0.3610.366-0.005
10Y0.4420.382+0.060
4.5.4.2. Debt to Equity Ratio

Measures if Bionomics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bionomics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 29.7% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bionomics Ltd ADR:

  • The MRQ is 0.297. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.297. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.297TTM0.2970.000
TTM0.297YOY0.148+0.150
TTM0.2975Y0.911-0.614
5Y0.91110Y1.112-0.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2970.393-0.096
TTM0.2970.437-0.140
YOY0.1480.373-0.225
5Y0.9110.449+0.462
10Y1.1120.489+0.623
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bionomics generates.

  • Above 15 is considered overpriced but always compare Bionomics to the Biotechnology industry mean.
  • A PE ratio of -1.36 means the investor is paying $-1.36 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bionomics Ltd ADR:

  • The EOD is -0.172. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.355. Based on the earnings, the company is expensive. -2
  • The TTM is -1.355. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.172MRQ-1.355+1.183
MRQ-1.355TTM-1.3550.000
TTM-1.355YOY-6.302+4.947
TTM-1.3555Y-1.531+0.176
5Y-1.53110Y-0.766-0.766
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.172-2.243+2.071
MRQ-1.355-2.403+1.048
TTM-1.355-2.929+1.574
YOY-6.302-3.417-2.885
5Y-1.531-5.877+4.346
10Y-0.766-6.197+5.431
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bionomics Ltd ADR:

  • The EOD is -0.386. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.036. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.036. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.386MRQ-3.036+2.650
MRQ-3.036TTM-3.0360.000
TTM-3.036YOY-9.129+6.093
TTM-3.0365Y-2.433-0.603
5Y-2.43310Y-1.216-1.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.386-2.930+2.544
MRQ-3.036-3.181+0.145
TTM-3.036-3.471+0.435
YOY-9.129-4.579-4.550
5Y-2.433-7.975+5.542
10Y-1.216-8.636+7.420
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Bionomics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.95 means the investor is paying $1.95 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Bionomics Ltd ADR:

  • The EOD is 0.249. Based on the equity, the company is cheap. +2
  • The MRQ is 1.955. Based on the equity, the company is underpriced. +1
  • The TTM is 1.955. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.249MRQ1.955-1.706
MRQ1.955TTM1.9550.000
TTM1.955YOY3.490-1.535
TTM1.9555Y1.089+0.866
5Y1.08910Y0.544+0.544
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.2491.917-1.668
MRQ1.9551.972-0.017
TTM1.9552.210-0.255
YOY3.4902.363+1.127
5Y1.0893.580-2.491
10Y0.5444.206-3.662
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Bionomics Ltd ADR.

4.8.1. Institutions holding Bionomics Ltd ADR

Institutions are holding 27.048% of the shares of Bionomics Ltd ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Armistice Capital, LLC9.26030.0118122675912267590
2024-06-30Point72 Asset Management, L.P.2.38540.000631600000
2024-06-30UBS Group AG0.263403489724964251.3239
2024-06-30TWO SIGMA SECURITIES, LLC0.19660.000226038260380
2024-06-30Lewis Asset Management LLC0.17360.013523000800053.3333
2024-06-30Two Sigma Investments LLC0.1236016370-700-4.1008
2024-06-30XTX Topco Ltd0.08260.000710940109400
2024-06-30Beacon Pointe Advisors, LLC0.07550.00011000000
2024-06-30Rhumbline Advisers0.01660219589068.1992
2024-06-30Morgan Stanley - Brokerage Accounts0.0060794606322.3404
2024-06-30Aspire Private Capital, LLC0.0015020000
2024-06-30JPMorgan Chase & Co00100
2024-03-31Bvf Inc000-47372-100
2024-03-31Octagon Capital Advisors LP000-168000-100
2024-03-31Tower Research Capital LLC000-1606-100
2024-03-31TANG CAPITAL MANAGEMENT LLC000-700000-100
Total 12.58510.02691667194+380519+22.8%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Net Interest Income  -1,406198-1,208236-971948-23327304



5.2. Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets28,643
Total Liabilities6,565
Total Stockholder Equity22,078
 As reported
Total Liabilities 6,565
Total Stockholder Equity+ 22,078
Total Assets = 28,643

Assets

Total Assets28,643
Total Current Assets13,385
Long-term Assets15,179
Total Current Assets
Cash And Cash Equivalents 12,155
Net Receivables 428
Inventory -428
Other Current Assets 1,229
Total Current Assets  (as reported)13,385
Total Current Assets  (calculated)13,385
+/-0
Long-term Assets
Property Plant Equipment 335
Goodwill 8,715
Intangible Assets 6,129
Other Assets 79
Long-term Assets  (as reported)15,179
Long-term Assets  (calculated)15,258
+/- 79

Liabilities & Shareholders' Equity

Total Current Liabilities2,750
Long-term Liabilities3,812
Total Stockholder Equity22,078
Total Current Liabilities
Short-term Debt 114
Accounts payable 1,374
Other Current Liabilities 1,377
Total Current Liabilities  (as reported)2,750
Total Current Liabilities  (calculated)2,865
+/- 114
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt419
Long-term Liabilities Other 3,687
Long-term Liabilities  (as reported)3,812
Long-term Liabilities  (calculated)4,106
+/- 294
Total Stockholder Equity
Common Stock148,803
Retained Earnings -136,386
Accumulated Other Comprehensive Income 9,656
Other Stockholders Equity 6
Total Stockholder Equity (as reported)22,078
Total Stockholder Equity (calculated)22,078
+/-0
Other
Capital Stock223,413
Cash and Short Term Investments 12,155
Common Stock Shares Outstanding 8,160
Current Deferred Revenue-114
Liabilities and Stockholders Equity 28,626
Net Debt -11,800
Net Invested Capital 33,148
Net Tangible Assets 10,861
Net Working Capital 15,966
Property Plant and Equipment Gross 927
Short Long Term Debt Total 355



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-30
> Total Assets 
213
5,308
10,829
15,839
12,571
14,962
17,050
19,715
30,821
28,313
24,725
31,514
34,309
31,102
53,611
65,061
69,132
66,904
64,618
48,158
37,672
23,784
40,689
45,091
28,643
28,64345,09140,68923,78437,67248,15864,61866,90469,13265,06153,61131,10234,30931,51424,72528,31330,82119,71517,05014,96212,57115,83910,8295,308213
   > Total Current Assets 
213
4,688
9,964
8,833
6,203
8,971
9,438
5,158
13,955
8,856
5,888
13,896
24,886
21,738
30,715
39,518
37,881
43,272
41,871
26,586
17,644
5,751
23,191
28,867
13,385
13,38528,86723,1915,75117,64426,58641,87143,27237,88139,51830,71521,73824,88613,8965,8888,85613,9555,1589,4388,9716,2038,8339,9644,688213
       Cash And Cash Equivalents 
86
523
1
8,592
6,070
8,703
9,005
4,728
12,821
6,280
4,757
12,612
16,052
17,337
22,452
10,500
26,558
33,859
32,952
18,452
9,819
3,159
21,370
23,174
12,155
12,15523,17421,3703,1599,81918,45232,95233,85926,55810,50022,45217,33716,05212,6124,7576,28012,8214,7289,0058,7036,0708,592152386
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
26
0
36
0
0
550
550
550
550
386
0
327
0
0
003270386550550550550003602600000000000
       Net Receivables 
0
73
85
99
27
135
141
242
339
2,315
775
847
8,449
411
706
20,740
1,064
922
634
417
569
12
145
4,665
428
4284,665145125694176349221,06420,7407064118,4498477752,315339242141135279985730
       Other Current Assets 
127
78
26
68
34
56
9
35
593
38
7
26
96
3,109
7,000
7,515
8,105
8,164
7,958
7,354
6,790
2,579
1,676
5,693
1,229
1,2295,6931,6762,5796,7907,3547,9588,1648,1057,5157,0003,10996267385933595634682678127
   > Long-term Assets 
0
620
866
7,006
6,367
5,991
7,611
14,557
16,866
19,457
18,837
17,618
9,423
9,364
22,896
25,543
31,251
23,347
22,452
21,287
19,758
17,732
17,410
16,143
15,179
15,17916,14317,41017,73219,75821,28722,45223,34731,25125,54322,8969,3649,42317,61818,83719,45716,86614,5577,6115,9916,3677,0068666200
       Property Plant Equipment 
0
435
724
6,906
6,311
5,977
5,654
5,646
8,628
8,618
8,379
7,908
303
773
843
828
3,451
2,112
2,012
2,031
1,760
728
653
466
335
3354666537281,7602,0312,0122,1123,4518288437733037,9088,3798,6188,6285,6465,6545,9776,3116,9067244350
       Goodwill 
0
0
0
0
0
0
1,956
2,177
2,127
5,148
5,148
5,148
5,148
5,148
5,148
9,488
10,489
9,268
9,426
9,229
8,959
8,884
9,299
8,884
8,715
8,7158,8849,2998,8848,9599,2299,4269,26810,4899,4885,1485,1485,1485,1485,1485,1482,1272,1771,956000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
384
384
436
119
0
0
001194363843840000000000000000000
       Intangible Assets 
0
184
142
99
57
14
1
6,734
6,110
5,691
5,310
4,563
3,972
3,372
16,905
15,226
16,928
11,966
11,014
10,027
9,038
8,120
7,458
6,793
6,129
6,1296,7937,4588,1209,03810,02711,01411,96616,92815,22616,9053,3723,9724,5635,3105,6916,1106,73411457991421840
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
284
270
301
89
82
79
7982893012702840000000000000000000
> Total Liabilities 
758
246
642
5,850
5,856
6,031
6,371
8,768
8,122
6,786
6,030
6,049
5,610
5,203
12,204
20,242
37,166
34,005
33,527
35,607
26,088
15,032
4,998
5,798
6,565
6,5655,7984,99815,03226,08835,60733,52734,00537,16620,24212,2045,2035,6106,0496,0306,7868,1228,7686,3716,0315,8565,850642246758
   > Total Current Liabilities 
708
174
592
843
1,230
1,405
2,035
2,681
3,613
3,051
2,791
3,236
5,480
4,468
6,083
9,281
13,706
8,482
10,675
9,832
9,690
5,709
1,770
2,317
2,750
2,7502,3171,7705,7099,6909,83210,6758,48213,7069,2816,0834,4685,4803,2362,7913,0513,6132,6812,0351,4051,230843592174708
       Short-term Debt 
200
0
22
127
508
508
358
414
542
572
529
627
2,828
733
680
789
5,460
2,034
6,517
4,209
5,931
4,099
131
110
114
1141101314,0995,9314,2096,5172,0345,4607896807332,828627529572542414358508508127220200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,834
8,452
5,185
0
0
0
0005,1858,4525,8340000000000000000000
       Accounts payable 
508
151
154
345
350
524
958
1,077
2,120
1,725
1,137
1,384
1,357
1,991
3,272
2,663
3,933
1,962
1,460
2,670
844
871
771
1,075
1,374
1,3741,0757718718442,6701,4601,9623,9332,6633,2721,9911,3571,3841,1371,7252,1201,077958524350345154151508
       Other Current Liabilities 
0
22
366
248
351
323
563
1,945
1,683
1,026
2,042
1,154
1,247
1,726
2,092
2,561
4,237
6,521
9,214
7,163
2,756
4,838
999
1,242
1,377
1,3771,2429994,8382,7567,1639,2146,5214,2372,5612,0921,7261,2471,1542,0421,0261,6831,945563323351248366220
   > Long-term Liabilities 
50
72
50
5,007
4,626
4,626
4,335
6,087
4,509
3,735
3,239
2,813
130
735
6,122
10,961
23,460
13,735
7,696
11,647
6,913
4,320
3,232
3,467
3,812
3,8123,4673,2324,3206,91311,6477,69613,73523,46010,9616,1227351302,8133,2393,7354,5096,0874,3354,6264,6265,007507250
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,087
13,511
7,224
3,612
4,508
5,365
5,3654,5083,6127,22413,51119,0870000000000000000000
> Total Stockholder Equity
-545
5,062
10,187
9,989
6,715
8,931
10,679
10,946
22,699
21,527
18,695
25,466
28,699
25,899
41,407
44,819
31,966
32,900
31,092
12,551
11,583
8,752
35,691
39,294
22,078
22,07839,29435,6918,75211,58312,55131,09232,90031,96644,81941,40725,89928,69925,46618,69521,52722,69910,94610,6798,9316,7159,98910,1875,062-545
   Common Stock
376
7,402
15,806
19,098
20,365
26,155
32,792
38,038
52,834
56,099
59,970
75,114
87,691
87,835
111,313
111,722
111,990
100,118
103,402
100,075
101,758
102,247
142,614
150,301
148,803
148,803150,301142,614102,247101,758100,075103,402100,118111,990111,722111,31387,83587,69175,11459,97056,09952,83438,03832,79226,15520,36519,09815,8067,402376
   Retained Earnings -136,386-119,654-115,507-102,752-99,737-97,219-83,157-75,574-86,567-69,618-72,824-62,823-59,687-52,836-44,622-37,759-32,975-27,526-21,857-17,224-13,650-9,109-5,619-2,340-921
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,356
10,847
9,695
4
22
-10
35
6
635-102249,69510,8478,35600000000000000000



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.